BRIEF—Morningside-backed Adiso Therapeutics launches today

Today, Adiso Therapeutics came out of stealth mode, announcing its financing, mission and leadership.

Backed by Morningside Ventures, USA-based Adiso is a clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating inflammatory diseases.

Adiso is advancing an innovative pipeline of small molecules with novel mechanisms of action and single strain live biotherapeutic products (SSLBP), pursuing lead indications in ulcerative colitis, and C. difficile infection (CDI).

In addition to two Phase I programs (UC & CDI) and a Phase II program (UC), Adiso has a novel inflammasome program in discovery phase which is being initially explored in respiratory inflammation, with multiple future potential therapeutic areas to pursue.

CEO and CMO appointments

Adiso also announced today the appointment of Scott Megaffin as chief executive.

Mr Megaffin has 30+ years of industry experience and a successful track record in senior leadership roles at Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, and Churchill.

Most recently, he served as CEO of Adastra Pharmaceuticals, an oncology clinical-stage development company, where he guided the company to a successful transaction with Cothera Bioscience in October 2021.

Dr Mustafa Noor, has also joined the Adiso leadership team, taking on the position of chief medical officer, bringing more than 20 years of drug development expertise across multiple therapeutic areas in multiple early- to mid-stage and global companies including AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, GlaxoSmithKline, and Bristol Myers Squibb.